TWI879917B - 二唑衍生物 - Google Patents
二唑衍生物 Download PDFInfo
- Publication number
- TWI879917B TWI879917B TW110109295A TW110109295A TWI879917B TW I879917 B TWI879917 B TW I879917B TW 110109295 A TW110109295 A TW 110109295A TW 110109295 A TW110109295 A TW 110109295A TW I879917 B TWI879917 B TW I879917B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- compound
- alkyl
- substituted
- alkoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020046138 | 2020-03-17 | ||
| JP2020-046138 | 2020-03-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202146392A TW202146392A (zh) | 2021-12-16 |
| TWI879917B true TWI879917B (zh) | 2025-04-11 |
Family
ID=77768228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110109295A TWI879917B (zh) | 2020-03-17 | 2021-03-16 | 二唑衍生物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20230265061A1 (https=) |
| EP (1) | EP4122923B1 (https=) |
| JP (2) | JP7637121B2 (https=) |
| KR (1) | KR20220154208A (https=) |
| CN (1) | CN115515943B (https=) |
| AU (1) | AU2021239631A1 (https=) |
| BR (1) | BR112022017530A2 (https=) |
| CA (1) | CA3170273A1 (https=) |
| DK (1) | DK4122923T3 (https=) |
| ES (1) | ES3041051T3 (https=) |
| FI (1) | FI4122923T3 (https=) |
| MX (1) | MX2022011483A (https=) |
| PH (1) | PH12022552373A1 (https=) |
| PT (1) | PT4122923T (https=) |
| TW (1) | TWI879917B (https=) |
| WO (1) | WO2021187486A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021187486A1 (ja) * | 2020-03-17 | 2021-09-23 | 大日本住友製薬株式会社 | オキサジアゾール誘導体 |
| JP7653399B2 (ja) | 2021-09-22 | 2025-03-28 | 住友ファーマ株式会社 | オキサジアゾール誘導体を含有する医薬組成物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009071576A1 (en) * | 2007-12-05 | 2009-06-11 | Glaxo Group Limited | 5-aryl-1,3,4-oxadiazole-2-amines as nicotinic acetylcholine receptor agonists |
| TWI324602B (en) * | 2005-12-23 | 2010-05-11 | Hoffmann La Roche | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
| WO2017075312A1 (en) * | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1227978A (https=) * | 1968-09-13 | 1971-04-15 | ||
| TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
| EP2109364A4 (en) * | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
| RU2010142655A (ru) * | 2008-03-19 | 2012-04-27 | Ауриммед Фарма, Инк. (Us) | Соединение, пригодное для лечения болезней и нарушений центральной нервной системы, и способ его получения |
| US8691824B2 (en) * | 2008-08-04 | 2014-04-08 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| JPWO2010055911A1 (ja) * | 2008-11-14 | 2012-04-12 | 大日本住友製薬株式会社 | ビフェニルアセトアミド誘導体 |
| WO2011145669A1 (ja) * | 2010-05-19 | 2011-11-24 | 大日本住友製薬株式会社 | アミド誘導体 |
| JP2012001537A (ja) * | 2010-05-19 | 2012-01-05 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体からなる医薬 |
| US9199981B2 (en) * | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| WO2013062027A1 (ja) * | 2011-10-27 | 2013-05-02 | 大正製薬株式会社 | アゾール誘導体 |
| JP2013221025A (ja) * | 2012-04-19 | 2013-10-28 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体の製造方法及びその中間体 |
| US20150299178A1 (en) * | 2012-11-12 | 2015-10-22 | Lupin Limited | Thiazole Derivatives as Alpha 7 NACHR Modulators |
| JP6387669B2 (ja) * | 2013-04-26 | 2018-09-12 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
| WO2015161014A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| TW201642855A (zh) | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| WO2017066103A1 (en) * | 2015-10-16 | 2017-04-20 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| WO2021187486A1 (ja) * | 2020-03-17 | 2021-09-23 | 大日本住友製薬株式会社 | オキサジアゾール誘導体 |
-
2021
- 2021-03-16 WO PCT/JP2021/010628 patent/WO2021187486A1/ja not_active Ceased
- 2021-03-16 ES ES21770862T patent/ES3041051T3/es active Active
- 2021-03-16 PT PT217708627T patent/PT4122923T/pt unknown
- 2021-03-16 US US17/905,847 patent/US20230265061A1/en active Pending
- 2021-03-16 MX MX2022011483A patent/MX2022011483A/es unknown
- 2021-03-16 CA CA3170273A patent/CA3170273A1/en active Pending
- 2021-03-16 TW TW110109295A patent/TWI879917B/zh active
- 2021-03-16 DK DK21770862.7T patent/DK4122923T3/da active
- 2021-03-16 PH PH1/2022/552373A patent/PH12022552373A1/en unknown
- 2021-03-16 AU AU2021239631A patent/AU2021239631A1/en active Pending
- 2021-03-16 JP JP2022508381A patent/JP7637121B2/ja active Active
- 2021-03-16 KR KR1020227035750A patent/KR20220154208A/ko active Pending
- 2021-03-16 BR BR112022017530A patent/BR112022017530A2/pt unknown
- 2021-03-16 FI FIEP21770862.7T patent/FI4122923T3/fi active
- 2021-03-16 EP EP21770862.7A patent/EP4122923B1/en active Active
- 2021-03-16 CN CN202180036916.0A patent/CN115515943B/zh active Active
-
2022
- 2022-09-16 US US17/932,871 patent/US11718592B2/en active Active
-
2025
- 2025-02-14 JP JP2025022409A patent/JP2025081449A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324602B (en) * | 2005-12-23 | 2010-05-11 | Hoffmann La Roche | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
| WO2009071576A1 (en) * | 2007-12-05 | 2009-06-11 | Glaxo Group Limited | 5-aryl-1,3,4-oxadiazole-2-amines as nicotinic acetylcholine receptor agonists |
| WO2017075312A1 (en) * | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220154208A (ko) | 2022-11-21 |
| TW202146392A (zh) | 2021-12-16 |
| US20230265061A1 (en) | 2023-08-24 |
| US11718592B2 (en) | 2023-08-08 |
| AU2021239631A8 (en) | 2022-12-01 |
| JPWO2021187486A1 (https=) | 2021-09-23 |
| PT4122923T (pt) | 2025-12-03 |
| AU2021239631A1 (en) | 2022-11-10 |
| JP7637121B2 (ja) | 2025-02-27 |
| ES3041051T3 (en) | 2025-11-06 |
| DK4122923T3 (da) | 2025-12-15 |
| FI4122923T3 (fi) | 2025-11-12 |
| CN115515943B (zh) | 2024-07-09 |
| PH12022552373A1 (en) | 2023-12-18 |
| MX2022011483A (es) | 2022-10-07 |
| EP4122923A1 (en) | 2023-01-25 |
| JP2025081449A (ja) | 2025-05-27 |
| CA3170273A1 (en) | 2021-09-23 |
| WO2021187486A1 (ja) | 2021-09-23 |
| EP4122923B1 (en) | 2025-09-10 |
| CN115515943A (zh) | 2022-12-23 |
| BR112022017530A2 (pt) | 2022-10-18 |
| EP4122923A4 (en) | 2024-04-24 |
| US20230092498A1 (en) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7470058B2 (ja) | 複素環化合物 | |
| JP5617919B2 (ja) | テトラヒドロベンゾチオフェン化合物 | |
| JP6020460B2 (ja) | アミノアルキル置換ｎ−チエニルベンズアミド誘導体 | |
| US8802679B2 (en) | Glycine compound | |
| JPWO2017170830A1 (ja) | 複素環化合物 | |
| JP6975515B2 (ja) | Ｔｒｐａ１モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物 | |
| US20100292266A1 (en) | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | |
| TW201738226A (zh) | 雜環化合物 | |
| CN112654608B (zh) | 具有脲结构的稠环化合物 | |
| CN105358547A (zh) | 作为强效rock1和rock2抑制剂的苯基吡唑衍生物 | |
| JP2025081449A (ja) | オキサジアゾール誘導体 | |
| WO2011016559A1 (ja) | 複素環化合物およびその用途 | |
| JP7561978B2 (ja) | ベンザミド類化合物及びその使用 | |
| JPWO2017155050A1 (ja) | 芳香環化合物 | |
| MX2014012992A (es) | Derivado de quinazolindiona. | |
| JPWO2019022179A1 (ja) | 複素環化合物 | |
| JP7653399B2 (ja) | オキサジアゾール誘導体を含有する医薬組成物 | |
| CN118541366A (zh) | 二氢噁唑衍生物化合物 | |
| RU2850795C1 (ru) | Производное тетрагидрохинолина и его медицинское применение | |
| HK40086571A (en) | Oxadiazole derivative | |
| JP2023045508A (ja) | イソオキサゾリン誘導体 | |
| HK40086571B (en) | Oxadiazole derivative | |
| EA048061B1 (ru) | Производное оксадиазола | |
| WO2025064325A1 (en) | Gpr35 modulators | |
| JP2025530975A (ja) | Ｉｒａｋ３結合剤としての置換イミダゾピラジン化合物 |